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Accepted 3 November 2014; Published online 6 November 2014AbstractObjectives: Cochrane Reviews should address the most important questions for guideline writers, clinicians, and the public. It is not
possible to keep all reviews up-to-date, so the Cochrane Airways Group (CAG) decided to prioritize updates and new reviews without re-
questing additional resources. The aim of the objective was to develop pragmatic and transparent prioritization techniques to identify 25 to
35 high-priority updates from a total of 270 CAG Reviews and become more selective over which new reviews we publish.
Study Design and Setting: We used elements from existing prioritization processes, including existing health care uncertainties, expert
opinion, and a decision tool. We did not conduct a full face-to-face workshop or an iterative group decision-making process.
Results: We prioritized 30 reviews in need of updating and aimed to update these within 2 years. Within the first 18 months, nine of
these have been published.
Conclusion: A pragmatic approach to prioritization can indicate priority reviews without an excessive drain on time and resources. The
steps provide us with better control over the reviews in our scope and can be built on in the future.  2015 The Authors. Published by
Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Health research should aim to answer questions of interest
to the public and health care providers. This is especially true
when research is funded by the public. For these reasons,
Cochrane Reviews, which are supported by public funding,
must seek to answer priority questions. This has been under-
lined in Cochrane’s strategy to 2020 [1]. End users, such asConflict of interest: E.W., E.S., and C.C. are funded as staff of the Co-
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licenses/by-nc-nd/3.0/).guideline writers, clinicians, and patients, expect reviews to
be both up-to-date and answer relevant clinical questions
in health care. Because of the challenges for individuals to
keep up with the rapidly expanding health care literature at
a time when there are 75 trials and 11 systematic reviews
published every day [2], it is important that the Cochrane Li-
brary contains reviews on the most important topics.
Historically, Cochrane Review topics have been pro-
posed by prospective authors, and decisions about when
to update a particular review were also motivated by author
teams. This has left the Cochrane Airways Group (CAG)
[3] and some other Cochrane Review Groups (CRG), with
a collection of systematic reviews, which have evolved over
time, rather than a carefully planned and curated collection
of reviewsdalthough this is done in some CRGs.
Although it is commonly held that health research prior-
ity setting processes help effectively target research, there
is no agreement on the best way of conducting such an ex-
ercise either generally [4] or within Cochrane [5]. Priority
setting processes have generally involved stakeholders such
as clinicians, guideline writers, patients, carers, and other
members of the public, who derive a list of key clinical
questions through a variety of methods such as question-
naires and face-to-face meetings. Pickard et al. [6]ess article under the CC BY-NC-ND license (http://creativecommons.org/
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Key findings
 We were able to prioritize 30 of 270 Cochrane Air-
ways Reviews for updating and made a commit-
ment to updating as many of these as possible
within 2 years. Nine of these reviews have been up-
dated in the first 18 months.
What this adds to what was known?
 Several approaches to research prioritization have
been published. We present a pragmatic approach
to prioritization of a Cochrane Review Group
(CRG) systematic review portfolio, which was
done without additional resources.
What is the implication and what should change
now?
 By using a variety of techniques for prioritization,
the Cochrane Airways Group was able to gain
more control over our scope. Similar approaches
may be of use to other CRG or others making de-
cisions about research priorities such as funders
and guideline developers.
prioritized comparative effectiveness research topics in
COPD using stakeholder involvement including face-to-
face discussions with clinicians and a separate meeting with
other stakeholders. A similar approach was reported by Li
et al. [7] where needs for primary research and systematic
reviews were evaluated in primary open-angle glaucoma.
1.1. Our aims
The aim of the study was to develop pragmatic and
transparent prioritization techniques to identify 25 to 35
high-priority updates from a total of 270 CAG Reviews
and become more selective over which new reviews we
publish.
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Our approach involved four different strands: (1) under-
standing patient uncertainties about asthma, (2) piloting a
prioritization tool to assess whether individual reviews
require updating, (3) surveying the CAG Editorial Board,
and (4) horizon scanning for new review titles.
2.1. Understanding patient uncertainties about asthma
The James Lind Alliance established an Asthma Priority
Setting Partnership (PSP) in 2004 [8]. We decided to use
the 267 treatment uncertainties and the top 10 priorityquestions identified by the PSP as a starting point for our
own prioritization. We grouped all the patient uncertainties
under ‘‘indicative domains’’ and revisited the top 10
research questions to highlight where new reviews or up-
dates were needed or where we already had a review rele-
vant to the uncertainty (see supporting information).
2.2. Decision tool for prioritizing Cochrane Review
updates
In 2011, a prioritization tool was developed by the Co-
chrane Collaboration and Bazian, to address issues around
updating systematic reviews [5,9]. The decision tool com-
prises a flowchart (Fig. 1) to support decision making,
and a statistical program run in STATA that assesses
whether the primary outcome of a review is likely to
change based on the number of new participants found in
new eligible studies. The flowchart guides the user through
a series of questions, and if there are new studies, the sta-
tistical decision tool can be applied to determine whether
conclusions are likely to change.
We piloted the tool on the top reviews ranked by Web
site hits and citations that had been identified by the Co-
chrane Library publisher, Wiley [10]. The information
specialist (ES) searched the CAG Specialized Register of
trials [11] as needed, and one person screened the titles
and abstracts for new studies for inclusion in the reviews.
We used the STATA tool on reviews where we had identi-
fied new eligible studies.
2.3. Survey of CAG Editorial Board
To obtain a perspective across all Cochrane Airways Re-
views, we asked the Editorial Board for input. The Editorial
Board comprises clinicians and researchers who have writ-
ten one or more reviews and who are involved in the selec-
tion of new review topics and editing reviews. We invited
14 Editors to select their top 10 reviews from a list of
185 published reviews and score them from 10 to 1, with
10 being most important. We did not ask the Editors to
consider all 270 reviews as we knew that approximately
90 had no new trials.
2.4. Prioritization of new review titles by horizon
scanning
The information specialist searches multiple databases
weekly to identify new trial reports to add to the Special-
ized Register of trials [11]. New and emerging treatments
were discussed at editorial team meetings. If a treatment
was an active research area (judged by the volume of refer-
ences to studies coming through in the literature), we
created a possible new review title on Cochrane’s informa-
tion management system, Archie. We used this list of
possible new titles to cross-check with unsolicited review
proposals to inform our decisions about which new review
proposals to accept.
Table 1. Indicative domains
Fig. 1. Prioritization flowchart. Reproduced with permission from David Tovey, Copyright 2011.
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environment, for example, through enquiries from prospec-
tive author teams, discussions with authors, editors, and
referees, and we noticed that a particular topic, vitamin
D for asthma, was generating a lot of interest. We decided
to put out an open call for review proposals on this topic.
We advertised the review title by e-mailing all our authors,
editors, and peer referees and promoting the title on our
Web site and social media. The editorial team assessed
the applications against the following criteria: (1) skills
of the author team, (2) appropriateness of methods to
answer the clinical question [participants, interventions,
control, outcomes (PICO) and subgroup analysis], (3)
appropriate timeline for review production, (4) the
commitment to update, and (5) the mention of current
methodology in the application (eg, recognition of key
standards for Cochrane Reviews such as summary of find-
ings tables and risk of bias).Indicative domain
1 Side effects from nonspecified asthma medications
2 Side effects from steroids
3 Alternatives to drugs
4 Asthma management
5 Environmental/asthma triggers
6 What is the best device to deliver inhaled treatments?
7 Drugs for asthma exacerbations
8 Drugs for chronic asthma3. Results
3.1. Assessing patient uncertainties
Eight key areas of uncertainty were highlighted
including side effects of drugs, alternatives to pharmaceu-
tical interventions (eg, complementary or holistictherapies), asthma management, and educational interven-
tions (Table 1).
Concerns about the effect of steroids on growth emerged
as a key issue. Our existing review ‘‘beclomethasone for
asthma in children: effects on linear growth’’ [12] was over
10 years out of date and only included one type of inhaled
corticosteroid (ICS) although several different ICS are now
routinely used in clinical practice. We therefore commis-
sioned a suite of three reviews on the effect of ICS on
growth in children with asthma. Two reviews on the effects
of ICS on growth [13] and doseeresponse effects [14] are
published, and we have a protocol on the effect of inhaler
devices on growth [15]. We also commissioned a new re-
view on self-management interventions to replace a number
of existing management reviews. The remaining topics
344 E. Welsh et al. / Journal of Clinical Epidemiology 68 (2015) 341e346were either covered by existing reviews or beyond the
scope of our group (see supporting information).
3.2. Piloting the decision tool
We planned to apply the decision tool to the reviews that
were most highly cited (N5 12) or had the mostWeb site hits
(N5 12). After removing duplicates (N5 3), reviews that had
recently been updated (N5 3), a review which was indicated
previously asneeding splitting into smaller reviewsandone re-
view that was in the process of being updated, we had 16 re-
views to test using the decision tool (Fig. 2).
For two reviews, we judged that the clinical question had
already been answered because the conclusions were firm
and the treatments were widely accepted in clinical practice.
We identified at least one new factor that would require a
change in scope in the remaining 14 reviews for example:
 Question answered in adults but more research
needed in children/neonates.
 Therapy vs. placebo answereddneed more informa-
tion on head-to-head comparisons.
 Some overlap with another review, therefore consid-
ered changing the inclusion criteria.
 The inclusion criteria led to heterogeneity in the study
methods and aims.
Because deciding whether the conclusions were likely to
change with these new factors constituted a substantive
piece of work, we brought all 14 reviews to the next step.Fig. 2. Flow diagram of reviews.We were confident that there were new studies for four
of these reviews, but we were less confident about the num-
ber of new studies for the remaining 10 reviews. We there-
fore tested these four reviews using the STATA tool. All
four reviews were indicated for updating as there were suf-
ficient participants in the trials to change the conclusions of
the review according to the algorithm.
Overall, we identified 14 of 21 reviews that needed up-
dating. We estimated that the piece of work took approxi-
mately five person-days of time.
3.3. Survey of CAG Editorial Board
Ten of 14 Editors responded to our request to select the
10 most important review updates from our portfolio.
Several Editors felt it was too difficult to give the reviews
a score, so we decided to adapt our scoring and give a re-
view a point each time an Editor nominated it in their
top 10.
Seventy-one reviews were identified by one or more Ed-
itors, and we added these to the 24 reviews that were most
highly accessed or cited. After removing duplicates, there
were 79 reviews. The next step was to reduce these in num-
ber to our target of around 24 reviews. To achieve this, we
decided to keep reviews that were identified by either two or
more Editors, or one Editor and a top hit or citation. We
added one review that had been identified through discus-
sion with a guideline team as an important review to update
for a forthcoming asthma guideline. From the remaining 45
reviews, 15 were identified as being up-to-date (n 5 6, hav-
ing had an update published within the previous 6 months),
in the editorial process (n 5 5), or update in progress
(n 5 4). Thirty were identified as a priority for updating.
3.4. Prioritization of new review titles
From a list of new and emerging treatments compiled
over 2012 to 2013 through surveillance of new trial litera-
ture, six titles were registered with a review team and a
further four were logged for further prioritization.
During 2012 and 2013, we received several expressions
of interest in working on a Cochrane Review on vitamin D
for asthma. Our open call for proposals resulted in 13 appli-
cations, and from these, we were able to successfully
appoint a review team. The protocol for this title is now
in development. We also registered a separate title on
vitamin D with a second review team for the prevention
of asthma, eczema, hay fever, and food allergy, which
had been mentioned in one of the applicationsdon which
we will collaborate with the Cochrane Ear, Nose and
Throat, and Skin Groups.4. Commentary
In this program of work, we used elements from an ex-
isting prioritization process, invited expert opinion, and
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that it is possible for CRGs to adopt a pragmatic approach
to prioritizing updates and new reviews based on informa-
tion that is likely to be already available to them.
This project differs from the approaches described in the
literature to date because we did not follow a formal meth-
odology. However, we had distinct aims against which we
can evaluate the success of this project. We achieved our
aims by prioritizing 30 reviews for updating, and we used
horizon scanning to prioritize new review titles. We
commissioned many of the updates and new reviews by
contacting existing review teams and asked them to update
their review or pass on the review to a new team for updat-
ing. We also suggested revisions to the methodology and
PICO question in some instances. Nine reviews have been
published, and one is in press.
Grounding our work in patient uncertainties derived
from earlier work was a strength of the project. Although
this might seem like an advantage which is not readily
available to all other Cochrane Groups, we have found it
is possible to acquire similar information from charities.
Since the completion of our prioritization exercise, Asthma
UK has kindly provided us with some information from
their patient groups and projects in the area of asthma man-
agement, and we are going to use this information in future
prioritization work.
Gathering the opinions from our Editorial Board was a
valuable exercise as Editors hold a wealth of clinical and
research experience and offer perspectives from the United
Kingdom, Europe, Australia, and Canada. This exercise
highlighted that we had only two pediatricians, only one
Editor based on an Emergency Department, and no Editors
from low- and middle-income countries. This is an outcome
of this project that we did not predict and we are working to
redress this imbalance.
Piloting the decision flowchart was an important part of
our exercise as it helped us to consider all the different fac-
tors that might indicate a need for updating. Piloting the
tool using a random selection of review topics rather than
the top hits and cites would have been a better test as our
test set of reviews had already been identified as highly ac-
cessed. However, because such a high proportion of these
highly cited reviews was also identified as priority for up-
dating by the decision tool, this pilot suggested that the
top hits and cites can be used by all CRGs to prioritize their
updates with very little extra work.
The labor intensive part of piloting the decision flow-
chart was screening the literature searches. In particular,
screening the literature searches for reviews of complex in-
terventions, such as education and pulmonary rehabilita-
tion, was a time-consuming task because of the difficulty
in applying inclusion criteria and the frequent need to
retrieve the full text to make a decision. In contrast, it is
relatively straightforward to screen a search for an update
of a placebo-controlled drug trial. In cases where more than
a few studies of complex interventions appear relevant fromthe abstract, we suggest that these reviews are assumed to
have new relevant data, even if they become ‘‘excluded
studies,’’ and are prioritized for updating. However, deci-
sions to update should not be indicated only by investiga-
tion of the number of new eligible studies.
An advantage in using the STATA tool is that it returns a
clear statistical answer on the probability of whether the
conclusions of a review are likely to change if it is updated
with new studies. However, because the tool uses only the
number of participants in a new study regardless of whether
outcome data relevant to the review are presented, false
positives may be generated.
Lack of resources has been highlighted as a barrier to
prioritization by Bero et al. [16,17] and others; however,
we have shown that it is possible to accomplish a fairly
extensive program of work without additional resources
beyond those available to all Cochrane Groups. Although
prioritization takes time, it also gives permission for
CRGs to say no to author requests to update reviews,
which were not identified as a priority thus freeing re-
sources. We have provided this detailed narrative descrip-
tion to inspire other groups who wish to do more
prioritization and intend that this can be used as a jumping
off point, rather than a prescriptive method. Most of the
work was completed by editorial base staff, and we drew
heavily on the expertise and experience of our Editors and
editorial team. We were able to use everyday tasks such as
the routine screening of literature for our trials register to
inform the decisions we make about taking on new review
titles, and we took a proactive approach to commissioning
a new priority title by advertising it without incurring any
costs.
The benefits of prioritizing our work are already
becoming apparent. We have achieved greater control over
our review portfolio, and the time saved by no longer sup-
porting undesirable updates has given us an opportunity to
focus on other projects that are important to our stake-
holders, for instance disseminating the results of our re-
views and engaging with policy makers and guideline
developers. The next steps for us are to extend this work
into other areas in our scope. We have already started to
prioritize our bronchiectasis reviews using a different
method. We have commissioned an overview of Cochrane
Reviews [18], and the overview team has taken the
approach of mapping out the evidence from reviews and tri-
als in bronchiectasis against a framework devised in the
protocol. Frameworks for prioritization of other areas could
be informed by relevant clinical guidelines and from evi-
dence mapping projects such as the neurotrauma evidence
map [19].
There are a number of other possible approaches to pri-
oritization, which have their own benefits and limitations,
and many CRGs already do some element of prioritization,
but we hope that this article encourages groups yet to begin
to do so and for all groups to share their methods and
experiences.
346 E. Welsh et al. / Journal of Clinical Epidemiology 68 (2015) 341e3465. Conclusion
We successfully prioritized 30 reviews for updating and
selected 12 new reviews to be conducted. We have moved
into a major new phase in organizing our output and are
more able to focus on the most important systematic re-
views to maintain, giving more time for dissemination
and other activities. Taking pragmatic steps toward prioriti-
zation can furnish a list of priority reviews without exces-
sive drain on the time and resources of a CRG.Acknowledgments
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